医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Pharmatech and InQui Capital Team Up to Offer Development Services to Life Science Startups

2015年06月02日 PM10:06
このエントリーをはてなブックマークに追加


 

HAYWARD, Calif.

Pharmatech Associates and InQui Capital of Hong Kong today announced the Pharmatech Connect program, a collaboration bringing development opportunities to early stage life science technology companies in the areas of investments, market expansion and strategic alliances worldwide.

Pharmatech Connect is a program created by Pharmatech Associates to provide early to mid-stage life sciences companies with financial resources to enable and accelerate development. The program services include identification and introduction of investors to cover the full range of development costs encompassing expertise in: global regulatory, technical development, manufacturing and compliance requirements, strategic partnering, business development and global healthcare investment services.

“Leveraging our experience along with that of InQui Capital, Pharmatech Connect is intended to bring together resources to boost the development of novel; biologicals, pharmaceuticals and medical devices,” said Warren Baker, Chief Executive Officer, Pharmatech Associates. “The healthcare market is global, and we are working locally and globally with companies to develop better drugs and therapies that result in healthier populations.”

“InQui Capital is pleased to team up with Pharmatech Associates to help life sciences companies realize their business goals and expand into the China market, one of the largest in the world,” said Dr. Juliana Xu, InQui Capital.

About Pharmatech Associates

Pharmatech Associates provides consulting and services to the regulated life science industry. Pharmatech’s services cover four spheres of technical expertise that are necessary throughout the complete product development lifecycle: Product and Process Development, Compliance, Regulatory, and Validation. This interconnected framework of services denotes the Pharmatech EcosystemTM. Pharmatech advises clients that range in size from startups to large multi-national corporations on projects in Asia, Europe and North America from its headquarters in the San Francisco Bay Area.

About InQui Capital

InQui Capital Ltd. is a Hong Kong-based consulting and investment firm focusing on life science-related sectors. InQui serves as a gateway between China and the West by helping small to mid-size companies find strategic partners both locally and globally. Its founders have extensive experience and knowledge in the global health care market, ranging from fund raising, IPO, cross-border mergers & acquisitions, intellectual property and securities law. InQui assists clients from the inception of their business, grows with them through fund raising, technology transfers, corporate development, and builds them into leaders in their fields.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150602005130/en/

CONTACT

SIPR for Pharmatech
Judy Curtis, + 1 650-274-1509
judy@sipr.com
or
Pharmatech
Jerry
Beers, + 1 510-732-0177
jbeers@pharmatechassociates.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease